

No. 2008-1352

IN THE UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT

TRANTAFYLLOS TAFAS,

Plaintiff-Appellee,

and

SMITHKLINE BEECHAM CORPORATION
(doing business as GlaxoSmithKline),
SMITHKLINE BEECHAM PLC, and GLAXO GROUP LIMITED
(doing business as GlaxoSmithKline),

Plaintiffs-Appellees,

v.

JOHN J. DOLL, Acting Under Secretary of Commerce for Intellectual Property
and Acting Director of the United States Patent & Trademark Office, and
UNITED STATES PATENT AND TRADEMARK OFFICE,

Defendants-Appellants.

Appeal from the United States District Court For the Eastern District of Virginia
in Consolidated Case Nos. 1:07-CV-846 and 1:07-CV-1008,
Senior Judge James C. Cacheris

**JOINT CONSENT MOTION FOR A STAY
OF EN BANC PROCEEDINGS**

Appellants John J. Doll and the United States Patent and Trademark Office (collectively "USPTO"), Appellee Triantafyllos Tafas ("Tafas"), and Appellees SmithKline Beecham Corporation d/b/a GlaxoSmithKline, SmithKline Beecham plc, and Glaxo Group Limited d/b/a GlaxoSmithKline (collectively, "GSK"), hereby jointly and respectfully move this Court for an immediate stay of the en banc briefing and oral argument schedule in the above-captioned matter, until 60 days after the Senate confirms the pending nomination of the new Under Secretary of Commerce for Intellectual Property and Director of the United States Patent & Trademark Office.

Appellants' en banc brief is currently due August 5, 2009. Appellees' responsive brief would be due 20 days thereafter, and Appellants' reply seven days after that. Oral argument is scheduled for October 7, 2009. No party has previously sought or received any extension of time or stay relating to the en banc briefing and oral argument schedule. All parties consent to the relief requested in this motion. The reasons for this motion are set forth below.

BACKGROUND

1. On August 21, 2007, USPTO issued major new regulations governing patent prosecution. See "Changes To Practice for Continued Examination Filings, Patent Applications Containing Patentably Indistinct Claims, and Examination of

Claims in Patent Applications,” 72 Fed. Reg. 46,717 (Aug. 21, 2007).

2. Appellees GSK and Tafas brought suit in the United States District Court for the Eastern District of Virginia, challenging the validity of those new regulations. The district court granted summary judgment in favor of Appellees, found Rules 75, 78, 114, and 265 to be null and void, and enjoined the Office from enforcing them. See Tafas v. Dudas, 541 F. Supp.2d 805 (E.D. Va. 2008).

3. USPTO appealed to this Court. On March 20, 2009, this Court issued an opinion affirming in part and reversing in part the decision of the district court. This Court agreed with the district court that USPTO’s Rule 78 was invalid. This Court upheld the other three rules promulgated by USPTO against certain of Appellees’ challenges and remanded the remaining challenges and the case as a whole to the district court for further proceedings.

4. On July 6, 2009, this Court granted Appellees’ petitions for rehearing en banc. The Court ordered Appellants to file within 30 days an *en banc* brief discussing the issues addressed in the panel opinions. Appellees were ordered to file their brief 20 days thereafter, and Appellants’ reply brief seven days after that. The Court subsequently ordered oral argument on October 7, 2009.

ARGUMENT

For the reasons set forth below and in the accompanying declaration, Appellants and Appellees GSK and Tafas jointly and respectfully move this Court to stay all matters before the en banc court, including the briefing schedule and oral argument date.

On June 18, 2009, the President of the United States nominated David Kappos as Under Secretary of Commerce for Intellectual Property and Director of the United States Patent & Trademark Office. See McIntosh Decl. ¶ 3. The Senate Judiciary Committee has scheduled a hearing on the nomination on July 29, 2009. *Id.* A stay of proceedings before the en banc court is requested to give the new Director, if confirmed, an opportunity to examine the rules at issue in this case and determine what course the USPTO should take in the future with respect to those rules, including whether to rescind the rules. Depending on how the Director decides to proceed, the legal issues currently before the *en banc* Court may be significantly altered or may even be rendered moot, making it unnecessary for the Court to take further action.

All the parties jointly and respectfully request that this Court immediately stay all proceedings in the above-captioned matter, to continue until 60 days after the Senate confirms the new Director of the USPTO. See McIntosh Decl. ¶ 7.


Such a stay should provide sufficient time for the USPTO's new leadership to determine an appropriate course of action. No party would be prejudiced by the requested stay, and the status quo would remain during the duration of the stay. The challenged rules at issue are not currently being enforced by the USPTO, which is enjoined from implementing them, and the Office will not implement them during the requested stay. See McIntosh Decl. ¶ 5.

Upon the expiration of the stay, if briefing remains necessary in light of any intervening actions by the USPTO regarding the rules, the parties jointly request that Appellants be given 30 days from the expiration of the stay to file their brief to the en banc court; that Appellees be given 20 days thereafter to file their brief; and that Appellants be given 7 days after that to file their reply brief.

CONCLUSION


For the foregoing reasons and those set forth in the accompanying declaration, this Court should stay all en banc proceedings in this case, including briefing and oral argument, until 60 days after the nominated Under Secretary of Commerce for Intellectual Property and Director of the United States Patent & Trademark Office has been confirmed.

Respectfully submitted,



Scott R. McIntosh
Joshua Waldman
U.S. Department of Justice, Civil
Division
950 Pennsylvania Avenue, N.W.
Room 7232
Washington, DC 20530
(202) 514-0236


**ATTORNEYS FOR APPELLANTS
JOHN J. DOLL AND USPTO**



Steven J. Moore
James Nealon
Kelley Drye & Warren LLP
400 Atlantic Street
Stamford, CT 06901
(203) 351-8020

**ATTORNEY FOR APPELLEE
TRIANAFYLLOS TAFAS**

July 24, 2009



F. Christopher Mizzo
Jeffrey Bossert Clark
D. Sean Trainor
Kirkland & Ellis LLP
655 Fifteenth Street, N.W.
Washington, DC 20005
(202) 879-5000

John M. Desmarais
Peter J. Armenio
Kirkland & Ellis LLP
153 East 53rd Street
New York, NY 10022
(212) 446-4800

**ATTORNEYS FOR APPELLEES
SmithKline Beecham Corporation
d/b/a GlaxoSmithKline, SmithKline
Beecham plc, and Glaxo Group
Limited d/b/a GlaxoSmithKline**

United States Court of Appeals for the Federal Circuit

Tafas v. Doll

No. 2008-1352

**DECLARATION OF AUTHORITY TO SIGN
FOR ATTORNEY OF RECORD**

Pursuant to Federal Circuit Rule 47.3(d), and under penalty of perjury pursuant to 28 U.S.C. § 1746, I, Scott R. McIntosh, an attorney at the United States Department of Justice, do hereby certify that I have authority to sign the attached **Joint Consent Motion for a for a Stay of En Banc Proceedings** in Appeal No. 2008-1352, on behalf of Steven J. Moore, an attorney of record for Appellee Triantafyllos Tafas, and on behalf of F. Christopher Mizzo, an attorney of record for Appellee SmithKline Beecham Corporation d/b/a GlaxoSmithKline, SmithKline Beecham plc, and Glaxo Group Limited d/b/a GlaxoSmithKline.




Scott R. McIntosh

July 24, 2009

CERTIFICATE OF SERVICE

I hereby certify that on July 24, 2009, I caused to be filed an original and eighteen (18) copies of the foregoing JOINT CONSENT MOTION FOR A STAY OF EN BANC PROCEEDINGS by sending them by hand delivery to the Clerk of the Court. I further certify that on July 24, 2009, I caused to be served two copies of the foregoing motion by sending them via U.S. mail to counsel in the service list below.



Scott R. McIntosh

Service List

Christopher Mizzo
Jeffrey Bossert Clark
D. Sean Trainor
Kirkland & Ellis LLP
655 15th Street, N.W.
12th Floor
Washington, DC 20005

Carter G. Phillips
Virginia A. Seitz
Jeffrey P. Kushan
David L. Fitzgerald
SIDLEY AUSTIN LLP
1501 K St., N.W.
Washington, D.C. 20005

Steven J. Moore
James Nealon
Kelley, Drye & Warren LLP
400 Atlantic Street
Stamford, CT 06901-3229

Daniel B. Ravicher
Public Patent Foundation
1375 Broadway, Suite 600
New York, NY 10018

Craig Crandall Reilly
Richard McGettigan Reilly & West PC
1725 Duke St
Suite 600
Alexandria, VA 22314

Joseph D. Wilson III
Joanna Elizabeth Baden-Mayer
Kelley Drye & Warren, LLP
3050 K Street, N.W.
Suite 400
Washington, DC 20007-5108

Dawn-Marie Bey
King & Spalding LLP
1700 Pennsylvania Avenue
Suite 200
Washington, DC 20006

Jackson David Toof
Arent Fox LLP
1050 Connecticut Ave., NW
Washington, DC 20036-5339

Maurice Francis Mullins
Spotts Fain PC

411 E Franklin St
Suite 600
PO Box 1555
Richmond, VA 23218-1555

James Murphy Dowd
Wilmer Cutler Pickering Hale & Dorr LLP
1455 Pennsylvania Ave NW
Washington, DC 20004

Randall Karl Miller
Arnold & Porter LLP
1600 Tysons Blvd
Suite 900
McLean, VA 22102

Ronald A. Schechter
Arnold & Porter LLP
555 Twelfth Street, NW
Washington, DC 20004

Scott Jeffrey Pivnick
Pillsbury Winthrop Shaw Pittman LLP
1650 Tysons Blvd
Suite 1400
McLean, VA 22102

Kevin T. Kramer
Vincent J. Napoleon
Stephanie F. Goeller
Pillsbury Winthrop Shaw Pittman LLP
2300 N St NW
Washington, DC 20037-1122

Thomas J. O'Brien
Morgan, Lewis & Bockius
1111 Pennsylvania Ave, NW
Washington, DC 20004

Jerry R. Selinger
Morgan, Lewis & Bockius LLP
1717 Main Street, Suite 3200
Dallas, TX 75201

Charles Gorenstein
Birch Stewart Kolasch & Birch LLP
8110 Gatehouse Rd
PO Box 747
Falls Church, VA 22040-0747

Robert Emmett Scully, Jr.
Stites & Harbison, PLLC
1199 North Fairfax St.
Suite 900
Alexandria, VA 22314

Craig James Franco
Odin Feldman & Pittleman PC
9302 Lee Highway
Suite 1100
Fairfax, VA 22031

Matthew Christian Schruers
Computer & Communications Industry Association
900 17th St NW
Suite 1100
Washington, DC 20006

Jonathan Dyste Link
Townsend and Townsend and Crew LLP
1301 K St NW
9th Floor, East Tower
Washington, DC 20005

John C. Maginnis, III
1350 Connecticut Avenue, N.W.
Suite 301
Washington, DC 20036

Timothy A. Molino
Bingham McCutchen LLP
2020 K St NW
Washington, DC 20006

Mark Fox Evens
Kenneth Carrington Bass, III
Sterne, Kessler, Goldstein & Fox
1100 New York Ave NW
Suite 600
Washington, DC 20005

Robert C. Gill
Saul Ewing LLP
2600 Virginia Ave NW
Suite 1000
Washington, DC 20037

Kevin Michael Henry
Sidley Austin Brown & Wood LLP
1501 K St NW
Washington, DC 20005

Heath Hoglund

Dean Alderucci
CFPH, LLC
110 East 59th Street
New York, NY 10022

Blair Elizabeth Taylor
Covington & Burling
1201 Pennsylvania Ave NW
Washington, DC 20004-7566

David Wayne Long
Howrey Simon Arnold & White LLP
1299 Pennsylvania Ave NW
Washington, DC 20004

Jennifer Sue Martinez
Stanford Law School
559 Nathan Abbott Way
Stanford, CA 94305
(650) 725-2749

Robert Christian Bertin
Swidler Berlin LLP
3000 K St NW
Suite 300
Washington, DC 20007-5116
(202) 373-6672

Colby B. Springer
Carr & Ferrell LLP
2200 Geng Road
Palo Alto, CA 94303

Charles E. Miller
Dickstein Shapiro LLP
1177 Avenue of the Americas
47th Floor
New York, NY 10036

John M. Neukom
Susan Godfrey LLP
1201 Third Avenue, Suite 3800
Seattle, WA 98101

Matthew C. Rainey
Intellectual Ventures, LLC
227 Bellevue Way, PMB 502
Bellevue, WA 98004

Buckmaster De Wolf
General Electric Co.
3135 Easton Turnpike
Fairfield, CT 06828

Dolby Laboratories, Inc.

100 Potrero Avenue
San Francisco, CA 94103

Paul H. Berghoff
Jeffrey A. Steck
McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606

Arthur O. Klein
7 Half Mile Common
Westport, CT 06880

No. 2008-1352

IN THE UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT

TRIANAFYLLOS TAFAS,

Plaintiff-Appellee,

and

SMITHKLINE BEECHAM CORPORATION
(doing business as GlaxoSmithKline),
SMITHKLINE BEECHAM PLC, and GLAXO GROUP LIMITED
(doing business as GlaxoSmithKline),

Plaintiffs-Appellees,

v.

JOHN J. DOLL, Acting Under Secretary of Commerce for Intellectual Property
and Acting Director of the United States Patent & Trademark Office, and
UNITED STATES PATENT AND TRADEMARK OFFICE,

Defendants-Appellants.

Appeal from the United States District Court For the Eastern District of Virginia
in Consolidated Case Nos. 1:07-CV-846 and 1:07-CV-1008,
Senior Judge James C. Cacheris

**DECLARATION OF SCOTT R. McINTOSH IN SUPPORT OF
JOINT CONSENT MOTION FOR A STAY
OF EN BANC PROCEEDINGS**

I, Scott R. McIntosh, declare as follows, pursuant to Federal Circuit Rule 26(b)(5):

1. On March 20, 2009, the United States Court of Appeal for the Federal Circuit issued a decision in the above-captioned matter, reversing in part and affirming in part.

2. On July 6, 2009, this Court granted Appellees' petitions for rehearing en banc. The Court ordered Appellants to file within 30 days an *en banc* brief discussing the issues addressed in the panel opinions. Appellees were ordered to file their brief 20 days thereafter, and Appellants' reply brief seven days after that. The Court subsequently ordered oral argument on October 7, 2009.

3. On June 18, 2009, the President of the United States nominated David Kappos as Under Secretary of Commerce for Intellectual Property and Director of the United States Patent & Trademark Office. The Senate Judiciary Committee has scheduled a hearing on the nomination on July 29, 2009. See <http://judiciary.senate.gov/nominations/111thCongressExecutiveNominations/CommerceUnderSecretary-DavidKappos.cfm>.

4. Appellants respectfully request that this Court immediately stay all en banc proceedings, including the briefing and oral argument schedule, until 60 days after the nominated Director has been confirmed by the Senate. A stay of


proceedings before the en banc court is requested to give the new Director, if confirmed, an opportunity to examine the rules at issue in this case and determine what course the USPTO should take in the future with respect to those rules.

5. The requested stay would not prejudice any party. The rules that are at issue in this case are not currently being implemented by Appellants, and Appellants would not seek to implement the rules during the pendency of the requested stay.

6. Neither Appellants nor Appellees have previously requested or been granted any extension of time or stay relating to the en banc briefing or oral argument schedule.

7. Counsel for Appellees Tafas and GSK have consented to the requested stay.

I declare under penalty of perjury that the foregoing is true and correct.

A handwritten signature in black ink, appearing to read 'SRM', written over a horizontal line.

Scott R. McIntosh
U.S. Department of Justice, Civil Division
950 Pennsylvania Avenue, N.W.
Room 7259
Washington, DC 20530
(202) 514-4052

July 24, 2009

No. 2008-1352

IN THE UNITED STATES COURT OF APPEALS
FOR THE FEDERAL CIRCUIT

TRIANTAFYLLOS TAFAS,

Plaintiff-Appellee,

and

SMITHKLINE BEECHAM CORPORATION
(doing business as GlaxoSmithKline),
SMITHKLINE BEECHAM PLC, and GLAXO GROUP LIMITED
(doing business as GlaxoSmithKline),

Plaintiffs-Appellees,

v.

JOHN J. DOLL, Acting Under Secretary of Commerce for Intellectual Property
and Acting Director of the United States Patent & Trademark Office, and
UNITED STATES PATENT AND TRADEMARK OFFICE,

Defendants-Appellants.

Appeal from the United States District Court For the Eastern District of Virginia
in Consolidated Case Nos. 1:07-CV-846 and 1:07-CV-1008,
Senior Judge James C. Cacheris

**ORDER GRANTING JOINT CONSENT MOTION FOR A STAY
OF EN BANC PROCEEDINGS**

Upon consideration of the Joint Consent Motion for a Stay of En Banc Proceedings, which is unopposed, and for good cause shown;

IT IS SO ORDERED THAT:

The Joint Consent Motion for a Stay of En Banc Proceedings is GRANTED, and the en banc proceedings shall be stayed until 60 days after the current nominee for Under Secretary of Commerce for Intellectual Property and Director of the United States Patent & Trademark Office is confirmed by the United States Senate.

Dated: July __, 2009 _____